Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona Day

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Gastrointestinal Oncology|November 12, 2025
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registryFaisal Hayat, Simon Chiu, Ashleigh Stuart, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2025
A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping SmokingAlison Luk Young, Melissa McEnallay, Fiona Day, et al.
Cancer Research|November 10, 2012
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancerNicholas I Fleming, Robert N Jorissen, Dmitri Mouradov, et al.
The New England Journal of Medicine|June 3, 2022
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon CancerJeanne Tie, Joshua D Cohen, Kamel Lahouel, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2025
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trialJohn W K Chia, Eva Segelov, Yanhong Deng, et al.
The New England Journal of Medicine|June 2, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Gastrointestinal Oncology|November 12, 2025
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registryFaisal Hayat, Simon Chiu, Ashleigh Stuart, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2025
A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping SmokingAlison Luk Young, Melissa McEnallay, Fiona Day, et al.
Cancer Research|November 10, 2012
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancerNicholas I Fleming, Robert N Jorissen, Dmitri Mouradov, et al.
The New England Journal of Medicine|June 3, 2022
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon CancerJeanne Tie, Joshua D Cohen, Kamel Lahouel, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2025
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trialJohn W K Chia, Eva Segelov, Yanhong Deng, et al.
The New England Journal of Medicine|June 2, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 4